PRIA Healthcare Welcomes Sam Murray as Head of Regulatory and Quality

At PRIA, we meet MedTech companies where they are in their journey and stay with them as they grow. For more than 14 years, that has meant helping innovators navigate the reimbursement and market access challenges that stand between promising technology and the patients who need it. It has meant building strategies that are practical, defensible, and rooted in the realities of the U.S. healthcare system.

And increasingly, it has meant our clients asking us for more.

Over the past several years, we've seen a clear pattern: the MedTech companies we work with don't just need a reimbursement strategy in isolation. They need it connected to their regulatory pathway from the very beginning. The decisions made early in a product's lifecycle, about device classification, intended use and claims, clinical evidence, submission strategy, have direct downstream consequences for coverage, coding, and commercial success. When those decisions are made in silos, companies pay for it later.

That's why we made the decision to formally expand our service offerings, adding regulatory affairs and quality, and why we are thrilled to announce that Sam Murray has joined PRIA as our Head of Regulatory and Quality.

Bringing Reimbursement and Regulatory Together

Sam's addition to the PRIA team is a designed strategic expansion of how we support the full MedTech innovation journey, from early concept through successful commercialization.

For companies navigating complex regulatory pathways, the stakes are high, and the margin for error is slim. Whether it's a 510(k) submission, a De Novo request, PMA, or emerging or novel technologies strategy, the regulatory decisions a company makes early on shape what's possible, commercially, clinically, and financially. At PRIA, we believe those decisions should be made with reimbursement and market access in mind from the start, not retrofitted after the fact.

Sam brings more than a decade of experience doing exactly that kind of high-stakes, high-impact regulatory work across medical devices, diagnostics, combination products, and software-enabled technologies. His background spans U.S. regulatory strategy, global submissions, quality system development and remediation, design controls, risk management, and direct engagement with regulatory authorities. Before joining PRIA, Sam founded and led his own independent regulatory and quality consultancy and held senior leadership roles at Advanced Instruments and Formlabs, where he built and scaled global regulatory and quality organizations and led acquisition due diligence across multiple transactions.

Perhaps most notably, Sam began his career as a medical device investigator with the U.S. Food and Drug Administration, conducting domestic and international inspections. That experience, seeing how the FDA operates from the inside, gives him a perspective on regulatory risk and compliance that is essential to navigating the U.S. regulatory environment.

What This Means for Our Clients

Jeff Sirek, CEO of PRIA Healthcare, put it simply:

"Our clients are building medical devices that impact patient lives; they require partners who can support their efforts at every stage of their journey.  Adding world-class regulatory expertise to our “gold standard” reimbursement and market access services allows PRIA to go deeper, earlier, and have sustained, meaningful impact on their path to commercial success."

The essence of Sam's role at PRIA is designed not only as a standalone regulatory consultant, but to function as an integrated part of the broader strategic support we provide to our customers.  Sam shared his own perspective on why this opportunity resonated with him:

"I've spent my career helping companies navigate some of the most complex regulatory challenges in MedTech, and what drew me to PRIA was the opportunity to do that work in a way that's truly connected to the bigger picture. Regulatory strategy doesn't exist in a vacuum — it must ladder up to access, adoption, and ultimately, patients. I'm excited to build something here that helps companies make smart, efficient decisions early and makes a real difference for the companies we serve."

A Team Built for the Full Innovation Journey

PRIA was founded on the belief that patient access is not an afterthought; it's the whole point. Over 40,000 patients have gained access to innovative care through PRIA-supported programs, and that number continues to grow as we expand the depth of support we can offer to our clients.

Sam's arrival marks a meaningful chapter in that story. It reflects both where our clients are asking us to go and where we believe the most important work in MedTech strategy is headed: toward integration, toward earlier engagement, and toward partners who can see the full picture and help companies navigate it with confidence.

We're proud to have Sam on the team, and we're excited about what we'll be able to build together for the innovators who trust us with their most important challenges.

Advancing Innovation. Unlocking Access. Delivering Impact.

Want to learn more about PRIA Healthcare's regulatory, reimbursement, and market access services? We'd love to connect!